/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
MSCI Equity Indexes May 2019 Index Review
LONDON–(BUSINESS WIRE)–MSCI Inc. (NYSE:MSCI), a leading provider of research-based indexes and
analytics, announced the results of the May 2019 Semi-Annual Index
Review for the MSCI Equity Indexes – including the MSCI Global Standard,
MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Global Value
and Growth Indexes, the MSCI Frontier Markets, and MSCI Frontier Markets
Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small
Cap Indexes, the MSCI Pan-Euro and MSCI Euro Indexes, the MSCI US Equity
Indexes, the MSCI US REIT Index, the MSCI China A Indexes, MSCI China A
Onshore Indexes and the MSCI China All Shares Indexes. All changes will
be implemented as of the close of May 28, 2019. These changes have been
posted on the Index Review web page on MSCI’s web site at https://www.msci.com/index-review.
Inclusion of the MSCI Saudi Arabia Indexes in Emerging Markets:
Coinciding with this Index Review, MSCI will implement the first step of
the inclusion of the MSCI Saudi Arabia Indexes in the MSCI Emerging
Markets Indexes. Thirty Saudi Arabian securities will be added at half
of their FIF1-adjusted market capitalization, representing an
aggregate weight of 1.42% in the MSCI Emerging Markets Index. The second
and final step of the inclusion will coincide with the August 2019
Quarterly Index Review.
Inclusion of the MSCI Argentina Indexes in Emerging Markets: MSCI
will reclassify the MSCI Argentina Indexes from Frontier Markets to
Emerging Markets in one step coinciding with this Index Review. Eight
Argentinian securities will be added at an aggregate weight of 0.26% in
the MSCI Emerging Markets Index.
Weight Increase of China A Shares in Emerging Markets: MSCI will
implement the first step of the weight increase of China A shares in the
MSCI Emerging Markets Indexes. Twenty-six China A shares (18 of which
are ChiNext stocks) will be added to the MSCI China Index and the
inclusion factor for 238 existing constituents will be increased from
0.05 to 0.10. China A shares will have an aggregate weight of 5.25% and
1.76% in the MSCI China and MSCI Emerging Markets Indexes, respectively.
As a reminder, the weight increase of China A shares in the MSCI
Emerging Markets Indexes will be implemented through a three-step
process. The FIF-adjusted market capitalization of China A shares will
be further increased to 0.15 as part of the August 2019 Quarterly Index
Review and then to 0.20, together with the inclusion of Mid Cap China A
shares, in the final step as part of the November 2019 Semi-Annual Index
Review.
MSCI has published the list of constituents of the MSCI Saudi Arabia,
MSCI Argentina and MSCI China A Indexes to reflect the results of the
May 2019 Semi-Annual Index Review at https://www.msci.com/market-classification.
In addition, MSCI has updated the list of China A Mid Cap securities
that may potentially be added to the MSCI China and the MSCI Emerging
Markets Indexes as part of the third step of the weight increase to be
implemented at the November 2019 Semi-Annual Index Review.
MSCI Global Standard Indexes: One hundred twenty-two securities
will be added to and 41 securities will be deleted from the MSCI ACWI
Index. In the MSCI World Index, the three largest additions measured by
full company market capitalization will be Knorr-Bremse (Germany), Snap
A (USA) and Twilio A (USA). The three largest additions to the MSCI
Emerging Markets Index measured by full company market capitalization
will be Saudi Basic Industries Corporation (Saudi Arabia), Saudi Telecom
Company (Saudi Arabia) and Al Rajhi Banking and Investment Corporation
(Saudi Arabia).
MSCI Global Small Cap Indexes: There will be 344 additions to and
195 deletions from the MSCI ACWI Small Cap Index.
MSCI Global Investable Market Indexes: There will be 400
additions to and 170 deletions from the MSCI ACWI Investable Market
Index (IMI).
MSCI Global All Cap Indexes: There will be 350 additions to and
148 deletions from the MSCI World All Cap Index.
MSCI Frontier Markets Indexes: There will be two additions to and
23 deletions from the MSCI Frontier Markets Index. The two additions to
the MSCI Frontier Markets Index will be Petrovietnam Power (Vietnam) and
Banque De Tunisie (Tunisia). There will be 12 additions to and 24
deletions from the MSCI Frontier Markets Small Cap Index.
MSCI will launch the MSCI Malta Investable Market Index as a Standalone
Index as part of the May 2019 Semi-Annual Index Review. The index will
initially include one Standard Size-Segment constituent and two Small
Cap Size-Segment constituents.
MSCI Global Islamic Indexes: Seventy-one securities will be added
to and 49 securities will be deleted from the MSCI ACWI Islamic Index.
The three largest additions to the MSCI ACWI Islamic Index measured by
full company market capitalization will be Abbott Laboratories (USA),
Saudi Basic Industries Corporation (Saudi Arabia) and Linde (New) (USA).
There will be no additions to and two deletions from the MSCI Gulf
Cooperation Council (GCC) Countries ex Saudi Arabia IMI Islamic Index.
MSCI US Equity Indexes: There will be seven securities added to
and four securities deleted from the MSCI US Large Cap 300 Index. The
three largest additions to the MSCI US Large Cap 300 Index measured by
full company market capitalization will be Xilinx, Arista Networks and
Transdigm Group Inc.
Thirty-one securities will be added to and 20 securities will be deleted
from the MSCI US Mid Cap 450 Index. The three largest additions to the
MSCI US Mid Cap 450 Index measured by full company market capitalization
will be Omnicom Group, Altice USA A and Apache Corporation.
One hundred fifty securities will be added to and 62 securities will be
deleted from the MSCI US Small Cap 1750 Index. The three largest
additions to the MSCI US Small Cap 1750 Index measured by full company
market capitalization will be Smartsheet A, ADT and Avnet.
There will be 49 additions to and 30 deletions from the MSCI US Micro
Cap Index.
For the MSCI US Investable Market Value Index, there will be 149
additions or upward changes in Value Inclusion Factor (VIFs), and 126
deletions or downward changes in VIFs. For the MSCI US Investable Market
Growth Index, there will be 196 additions or upward changes in Growth
Inclusion Factors (GIFs), and 128 deletions or downward changes in GIFs.
MSCI US REIT Index: There will be one addition to and two
deletions from the MSCI US REIT Index. The addition to the MSCI US REIT
Index will be Innovative Industrial Properties, Inc.
MSCI China A Indexes: There will be 26 additions to and no
deletions from the MSCI China A Large Cap Index resulting in 264 index
constituents. There will be 29 additions to and five deletions from the
MSCI China A Mid Cap Index resulting in 173 index constituents.
MSCI China A Onshore Indexes: There will be 109 additions to and
three deletions from the MSCI China A Onshore Index. The three largest
additions to the MSCI China A Onshore Index will be Wens Foodstuff Group
A, Contemporary A and Shenzhen Mindray A. There will be 503 additions to
and 49 deletions from the MSCI China A Onshore Small Cap Index. Most of
the additions are newly eligible ChiNext stocks.
MSCI China All Shares Indexes: There will be 66 additions to and
10 deletions from the MSCI China All Shares Index. The three largest
additions to the MSCI China All Shares Index will be Wens Foodstuff
Group A, Contemporary A and Shenzhen Mindray A. There will be 522
additions to and 46 deletions from the MSCI China All Shares Small Cap
Index. Most of the additions are newly eligible ChiNext stocks.
-Ends-
About MSCI
MSCI is a leading provider of critical decision support tools and
services for the global investment community. With over 45 years of
expertise in research, data and technology, we power better investment
decisions by enabling clients to understand and analyze key drivers of
risk and return and confidently build more effective portfolios. We
create industry-leading research-enhanced solutions that clients use to
gain insight into and improve transparency across the investment
process. To learn more, please visit www.msci.com.
This document and all of the information contained in it, including
without limitation all text, data, graphs, charts (collectively, the
“Information”) is the property of MSCI Inc. or its subsidiaries
(collectively, “MSCI”), or MSCI’s licensors, direct or indirect
suppliers or any third party involved in making or compiling any
Information (collectively, with MSCI, the “Information Providers”) and
is provided for informational purposes only. The Information may not be
modified, reverse-engineered, reproduced or redisseminated in whole or
in part without prior written permission from MSCI.
The Information may not be used to create derivative works or to verify
or correct other data or information. For example (but without
limitation), the Information may not be used to create indexes,
databases, risk models, analytics, software, or in connection with the
issuing, offering, sponsoring, managing or marketing of any securities,
portfolios, financial products or other investment vehicles utilizing or
based on, linked to, tracking or otherwise derived from the Information
or any other MSCI data, information, products or services.
The user of the Information assumes the entire risk of any use it may
make or permit to be made of the Information. NONE OF THE INFORMATION
PROVIDERS MAKES ANY EXPRESS OR IMPLIED WARRANTIES OR REPRESENTATIONS
WITH RESPECT TO THE INFORMATION (OR THE RESULTS TO BE OBTAINED BY THE
USE THEREOF), AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW,
EACH INFORMATION PROVIDER EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES
(INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF ORIGINALITY,
ACCURACY, TIMELINESS, NON-INFRINGEMENT, COMPLETENESS, MERCHANTABILITY
AND FITNESS FOR A PARTICULAR PURPOSE) WITH RESPECT TO ANY OF THE
INFORMATION.
Without limiting any of the foregoing and to the maximum extent
permitted by applicable law, in no event shall any Information Provider
have any liability regarding any of the Information for any direct,
indirect, special, punitive, consequential (including lost profits) or
any other damages even if notified of the possibility of such damages.
The foregoing shall not exclude or limit any liability that may not by
applicable law be excluded or limited, including without limitation (as
applicable), any liability for death or personal injury to the extent
that such injury results from the negligence or willful default of
itself, its servants, agents or sub-contractors.
Information containing any historical information, data or analysis
should not be taken as an indication or guarantee of any future
performance, analysis, forecast or prediction. Past performance does not
guarantee future results.
The Information should not be relied on and is not a substitute for the
skill, judgment and experience of the user, its management, employees,
advisors and/or clients when making investment and other business
decisions. All Information is impersonal and not tailored to the needs
of any person, entity or group of persons.
None of the Information constitutes an offer to sell (or a solicitation
of an offer to buy), any security, financial product or other investment
vehicle or any trading strategy.
It is not possible to invest directly in an index. Exposure to an asset
class or trading strategy or other category represented by an index is
only available through third party investable instruments (if any) based
on that index. MSCI does not issue, sponsor, endorse, market, offer,
review or otherwise express any opinion regarding any fund, ETF,
derivative or other security, investment, financial product or trading
strategy that is based on, linked to or seeks to provide an investment
return related to the performance of any MSCI index (collectively,
“Index Linked Investments”). MSCI makes no assurance that any Index
Linked Investments will accurately track index performance or provide
positive investment returns. MSCI Inc. is not an investment adviser or
fiduciary and MSCI makes no representation regarding the advisability of
investing in any Index Linked Investments.
Index returns do not represent the results of actual trading of
investible assets/securities. MSCI maintains and calculates indexes, but
does not manage actual assets. Index returns do not reflect payment of
any sales charges or fees an investor may pay to purchase the securities
underlying the index or Index Linked Investments. The imposition of
these fees and charges would cause the performance of an Index Linked
Investment to be different than the MSCI index performance.
The Information may contain back tested data. Back-tested performance is
not actual performance, but is hypothetical. There are frequently
material differences between back tested performance results and actual
results subsequently achieved by any investment strategy.
Constituents of MSCI equity indexes are listed companies, which are
included in or excluded from the indexes according to the application of
the relevant index methodologies. Accordingly, constituents in MSCI
equity indexes may include MSCI Inc., clients of MSCI or suppliers to
MSCI. Inclusion of a security within an MSCI index is not a
recommendation by MSCI to buy, sell, or hold such security, nor is it
considered to be investment advice.
Data and information produced by various affiliates of MSCI Inc.,
including MSCI ESG Research LLC and Barra LLC, may be used in
calculating certain MSCI indexes. More information can be found in the
relevant index methodologies on www.msci.com.
MSCI receives compensation in connection with licensing its indexes to
third parties. MSCI Inc.’s revenue includes fees based on assets in
Index Linked Investments. Information can be found in MSCI Inc.’s
company filings on the Investor Relations section of www.msci.com.
MSCI ESG Research LLC is a Registered Investment Adviser under the
Investment Advisers Act of 1940 and a subsidiary of MSCI Inc. Except
with respect to any applicable products or services from MSCI ESG
Research, neither MSCI nor any of its products or services recommends,
endorses, approves or otherwise expresses any opinion regarding any
issuer, securities, financial products or instruments or trading
strategies and MSCI’s products or services are not intended to
constitute investment advice or a recommendation to make (or refrain
from making) any kind of investment decision and may not be relied on as
such. Issuers mentioned or included in any MSCI ESG Research materials
may include MSCI Inc., clients of MSCI or suppliers to MSCI, and may
also purchase research or other products or services from MSCI ESG
Research. MSCI ESG Research materials, including materials utilized in
any MSCI ESG Indexes or other products, have not been submitted to, nor
received approval from, the United States Securities and Exchange
Commission or any other regulatory body.
Any use of or access to products, services or information of MSCI
requires a license from MSCI. MSCI, Barra, RiskMetrics, IPD and other
MSCI brands and product names are the trademarks, service marks, or
registered trademarks of MSCI or its subsidiaries in the United States
and other jurisdictions. The Global Industry Classification Standard
(GICS) was developed by and is the exclusive property of MSCI and
Standard & Poor’s. “Global Industry Classification Standard (GICS)” is a
service mark of MSCI and Standard & Poor’s.
MIFID2/MIFIR notice: MSCI ESG Research LLC does not distribute or act as
an intermediary for financial instruments or structured deposits, nor
does it deal on its own account, provide execution services for others
or manage client accounts. No MSCI ESG Research product or service
supports, promotes or is intended to support or promote any such
activity. MSCI ESG Research is an independent provider of ESG data,
reports and ratings based on published methodologies and available to
clients on a subscription basis. We do not provide custom or one-off
ratings or recommendations of securities or other financial instruments
upon request.
Privacy notice: For information about how MSCI ESG Research LLC collects
and uses personal data concerning officers and directors, please refer
to our Privacy Notice at https://www.msci.com/privacy-pledge.
1 Foreign Inclusion Factor
Contacts
Media Inquiries
PR@msci.com
Sam
Wang +1 212 804 5244
Melanie Blanco +1 212 981 1049
Laura
Hudson +44 20 7336 9653
MSCI Global Client Service
EMEA
Client Service + 44 20 7618.2222
Americas Client Service +1 888 588
4567 (toll free)
Asia Pacific Client Service + 852 2844 9333
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Innocan
Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center
HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.
The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.
Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.
“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”
Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html
Cannabis
Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location
- Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
- As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
- Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity
CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.
The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.
“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”
Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.
About Verano
Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf™ and MÜV™ dispensary banners, including Cabbage Club™, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano™, (the) Essence™, MÜV™, Savvy™, BITS™, Encore™, and Avexia™. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.
Contacts:
Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com
Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.
###
1 Pennsylvania Department of Transportation
2 United States Census Bureau
Cannabis
Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids
Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.
Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.
Global Minor Cannabinoids Market: Key Datapoints
|
Market Value in 2023 |
US$ 17.8 Bn |
|
Market Value Forecast by 2034 |
US$ 42.3 Bn |
|
Growth Rate
|
8.2% |
|
Historical Data
|
2016 – 2022 |
|
Base Year
|
2023 |
|
Forecast Data
|
2024 – 2034 |
Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.
The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.
The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.
The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.
Global Minor Cannabinoids Market: Key Takeaways of the Report
- Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
- Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
- In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.
Key Development:
- In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
- In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.
Browse Related Category Reports
Global Minor Cannabinoids Market:
- Aurora Europe GmbH
- BulKanna
- CBD. INC.
- Fresh Bros Hemp Company
- GCM Holdings, LLC (Global Cannabinoids)
- GenCanna.
- High Purity Natural Products.
- Laurelcrest
- Mile High Labs
- PBG Global
- Rhizo Sciences
- ZERO POINT EXTRACTION, LLC
- Other Industry Participants
Global Minor Cannabinoids Market
By Product Type
- Cannabigerol (CBG)
- Cannabichromene (CBC)
- Cannabinol (CBN)
- Cannabidivarin (CBDV)
- Tetrahydrocannabutol (THCB)
- Tetrahydrocannabivarin (THCV)
- Tetrahydrocannabiphorol (THCP)
- Others
By Application
- Pharmaceutical
- Pain Management
- Mental Health
- Sleep Disorders
- Anti-inflammatory
- Others
- Nutraceuticals
- Cosmetics and Personal Care
- Food and Beverages
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Consult with Our Expert:
Jay Reynolds
The Niche Research
Japan (Toll-Free): +81 663-386-8111
South Korea (Toll-Free): +82-808- 703-126
Saudi Arabia (Toll-Free): +966 800-850-1643
United Kingdom: +44 753-710-5080
United States: +1 302-232-5106
Email: askanexpert@thenicheresearch.com
Website: www.thenicheresearch.com
-
Cannabis2 weeks agoIM Cannabis Shares Commence Trading on 6:1 Consolidated Basis
-
Cannabis2 weeks agoFractional Flow Reserve Market growing at a CAGR of 15.56% during the forecast period [2024-2030] – Exactitude Consultancy
-
Cannabis1 week agoBlank Rome Bolsters Energy Industry Team in Houston and Pittsburgh with Leading Transactional Group
-
Cannabis1 week agoManitoba Harvest Hemp Foods and Brightseed® Introduce New Coffee and Chocolate Flavors in Organic Bioactive Fiber Supplement for Gut Health
-
Cannabis4 days agoEurope Medical Cannabis Oil Market Set to Reach Valuation of USD 2,395.83 Million by 2032 | Astute Analytica
-
Cannabis4 days agoGlobal Agricultural Textiles Market Size To Worth USD 25.02 Billion By 2033 | CAGR of 4.70%
-
Cannabis1 day ago
Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids
-
Cannabis14 hours ago
Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location